The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Дата публикации: 29-07-2026 05:07:44

SAN DIEGO, July 29, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that The Lancet, one of the most selective...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy	0	12.68	29-07-2026
2	Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel	0	13.9	30-07-2026
3	United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet	0	9.57	29-07-2026
4	Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)	0	17.8	26-05-2026
5	Ascelia Pharma Provides Update on the Orviglance NDA	0	11.3	03-07-2026
6	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility	0	13.33	07-08-2026
7	STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug	0	4.21	27-07-2026
8	Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile	0	16.82	10-08-2026
9	Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease	0	12.73	07-07-2026
10	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema	0	15.53	27-04-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.68. Источник: www.drugs.com.